Variable | Univariate | Multivariate | ||
---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Sex (men vs. women) | 1.204 (0.806–1.799) | 0.363 |  |  |
Age (<65 vs. ≥65 years) | 0.999 (0.983–1.016) | 0.934 |  |  |
Pathologic type (ccRCC vs. nccRCC) | 1.408 (0.896–2.221) | 0.138 |  |  |
History of nephrectomy (yes vs. no) | 1.103 (0.691–1.760) | 0.681 |  |  |
History of cytokine treatment (yes vs. no) | 0.963 (0.667–1.391) | 0.842 |  |  |
Fuhrman grade (1–2 vs. 3–4 and unknown) | 1.620 (1.260–2.081) | <0.001* | 1.495 (1.134–1.974) | 0.004 |
Number of metastatic sites (1 vs. ≥ 2) | 2.010 (1.384–2.918) | <0.001* | 1.736 (1.163–2.592) | 0.007 |
MSKCC risk category (favorable and intermediate vs. poor) | 1.927 (1.548–2.399) | <0.001* | 2.248 (1.759–2.871) | <0.001 |
NLR (<2.2 vs. ≥2.2) | 1.679 (1.201–2.347) | 0.002* | 1.804 (1.184–2.750) | 0.006 |
Drug category (sorafenib vs. sunitinib) | 1.036 (0.725–1.480) | 0.847 |  |  |
Pre-treatment serum albumin level (≥40.7 g/L vs. <40.7 g/L) | 1.407 (0.977–2.027) | 0.066 |  |  |
Post-treatment serum albumin level (≥36.4 g/L vs. <36.4 g/L) | 2.392 (1.637–3.494) | <0.001* | 2.388 (1.591–3.585) | <0.001 |